Genentech stops Erivedge IPF study before it starts
This article was originally published in Scrip
Genentech suspended patient recruitment for a Phase II clinical trial testing the hedgehog pathway inhibitor Erivedge (vismodegib) in the treatment of idiopathic pulmonary fibrosis (IPF) before the trial began enrolling patients.
You may also be interested in...
John Hood spent the past few years looking for a drug candidate worth forming a new company around before he zeroed in on Lilly’s taladegib as a treatment for idiopathic pulmonary fibrosis.
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.